|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from financial institutions | ||||||||||||||||||||
| Interest-earning deposits in other financial institutions | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Equity investments, at estimated fair value | ||||||||||||||||||||
| Securities available for sale, at estimated fair value (amortized cost of $624,955, at September 30, 2024 and $669,092 at December 31, 2023, net of allowance for credit losses of $0 at September 30, 2024 and December 31, 2023, respectively) | ||||||||||||||||||||
| Securities held to maturity | ||||||||||||||||||||
| Securities available for sale, at estimated fair value (amortized cost of $316,202, at June 30, 2026 and $327,888 at December 31, 2025, net of allowance for credit losses of $0 at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Securities held to maturity, at amortized cost (estimated fair value of $1,560 at June 30, 2026 and $640 at December 31, 2025, net of allowance for credit losses of $0 at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| FHLBNY and FRBNY stock, at cost | ||||||||||||||||||||
| Loans, net of deferred loan fees | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Interest rate swap assets | ||||||||||||||||||||
| Accrued interest receivable and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non interest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Overnight and short-term advances | ||||||||||||||||||||
| FRB term advance | ||||||||||||||||||||
| Subordinated debt, net of issuance costs of $921 and $972, respectively | ||||||||||||||||||||
| Long-term finance lease obligation | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Interest rate swap liabilities | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity: | ||||||||||||||||||||
| Common stock, $0.01 par value per share, 10,000,000 shares authorized; 5,310,076 issued at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost; $489,798 shares at June 30, 2026 and $519,079 shares at December 31, 2025 | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...
